Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04612725 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT04612725 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 159 participants.
The verdict
NCT04612725, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.
Interventions
- BIOLOGICAL Benralizumab
- BIOLOGICAL Placebo and Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04612725
The ClinicalTrials.gov registry entry for NCT04612725 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Benralizumab is the first listed.
NCT04612725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04612725 about?
NCT04612725 is a clinical study titled "A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)". The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.
What is the current status of trial NCT04612725?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2020-10-27. Estimated completion is 2023-03-28.
What interventions are being tested in trial NCT04612725?
The interventions under investigation include: Benralizumab (BIOLOGICAL), Placebo and Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04612725?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.